UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 FORM

 Mark
One

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended December 31, 2024

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from ______ to _______

 Commission
File No. 333-234487

 NOWTRANSIT
INC.

 (Exact
name of registrant as specified in its charter)

 Nevada

 7374

 98-1498782

 (State or Other Jurisdiction of
 Incorporation or Organization)

 (Primary Standard Industrial
 Classification Number)

 (IRS Employer
 Identification Number)

 2722
South West Temple

 Salt
Lake City, UT 84115

 (Address
of principal executive offices)

 Registrant's
telephone number, including area code: (801) 949-0791

 Securities
registered pursuant to Section 12(b) of the Act:

 Title of each class

 Trading Symbol(s)

 Name of each exchange on which registered

 None

 None

 None

 Securities
registered pursuant to Section 12(g) of the Act: Common Stock, par value $0.0001

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. Yes No

by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes No

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller
reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer
 Accelerated Filer

 Non-accelerated filer
 Smaller reporting company

 Emerging growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 Class

 Outstanding as of March 12, 2025

 Common Stock: $0.0001 par value

 43,916,221

 The
aggregate market value of the registrant's common stock held by non-affiliates on June 30, 2024, the last business day of the registrant's
most recently completed second quarter, was $ 41,596,221.

 TABLE
OF CONTENTS

 PART
 I

 ITEM

 Business

 ITEM
 1A

 Risk Factors

 ITEM 1B

 Cybersecurity

 ITEM

 Properties

 ITEM

 Legal Proceedings

 ITEM

 Mine Safety Disclosures

 PART
 II

 ITEM

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 ITEM

 Selected Financial Data

 ITEM

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 ITEM
 7A

 Quantitative and Qualitative Disclosures about Market Risk

 ITEM

 Financial Statements and Supplementary Data

 ITEM

 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 ITEM
 9A

 Controls and Procedures

 ITEM
 9B

 Other Information

 ITEM
 9C

 Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 PART
 III

 ITEM

 Directors, Executive Officers and Corporate Governance

 ITEM

 Executive Compensation

 ITEM

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 ITEM

 Certain Relationships and Related Transactions, and Director Independence

 ITEM

 Principal Accountant Fees and Services

 PART
 IV

 ITEM

 Exhibits

 ITEM

 Form 10-K Summary

 PART
I

 Item
1. Business

 FORWARD-LOOKING
STATEMENTS

 This
annual report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements regarding our ability to locate and acquire an operating business, the status of our current acquisition opportunity and the
resources and efforts we intend to dedicate to such an endeavor, our development of a viable business plan and our ability to locate
sources of capital necessary to meet our business needs and objectives. All statements other than statements of historical facts contained
in this Report, including statements that relate to our future financial performance, liquidity, business strategy and plans and objectives
of management for future operations, are forward-looking statements. These forward-looking statements often can be identified by the
use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate,"
"approximate," "should," "intend," "could," "potential," "is likely,"
"plan," "continue," and similar expressions. We have based these forward-looking statements largely on our current
expectations and projections about future events and financial trends that we believe may affect our financial condition, results of
operations, business strategy and financial needs.

 The
results anticipated by any or all of these forward-looking statements might not occur. Important factors, uncertainties and risks that
may cause actual results to differ materially from these forward-looking statements include those described in Item 1A. – Risk
Factors. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information,
future events or otherwise.

 General
Information

 Nowtransit
Inc. ("Nowtransit," "we," "the Company") was incorporated in the State of Nevada on July 8, 2019
and has a fiscal year end of December 31. Through March 10, 2023 we had not generated material revenues, had minimal assets and had incurred
losses since inception. We were formed to engage in the online delivery business, but in connection with the reverse merger described
in the following paragraph, the Company terminated its plans in the online delivery business. Since the reverse merger we've experienced
a change of control and we now sell clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses
through online sales and in various other distribution channels.

 Reverse
Merger

 On
February 13, 2023, Nowtransit Inc. entered into the Exchange Agreement with Best 365 Labs Inc. ("Best") and the shareholders
of Best who collectively owned 9,588,000 shares of Best common stock, or 100% of the outstanding shares of Best common stock. The transaction
consummated on March 10, 2023 (the "Closing").

 Upon
the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company's common stock, representing approximately
85.39% of the shares of the Company's common stock to be outstanding, in exchange for all of the shares of Best common stock held
by Best shareholders. The transaction was accounted for as a reserve merger. Best was the accounting acquirer and Nowtransit the accounting
acquiree. As such, the consolidated financial statements presented are the historical financial statements of Best with retroactive adjustments
to reflect the equity of Nowtransit. Since Nowtransit was the legal acquirer, the resulting financial statements are in the name of Nowtransit.

 Item
1A. Risk Factors

 Investing
in our common stock involves a high degree of risk. Investors should carefully consider the following Risk Factors before deciding whether
to invest in the Company. Additional risks and uncertainties not presently known to us, or that we currently deem immaterial, may also
impair our financial condition. If any of the events discussed in the Risk Factors below occur, our business, consolidated financial
condition, results of operations or prospects could be materially and adversely affected. In such case, the value and marketability of
our common stock could decline.

we have limited capital, we may need to raise additional capital in the future by issuing debt or equity securities, the terms of which
may dilute our current investors and/or reduce or limit their liquidation or other rights.

 The
terms of securities we issue in future capital raising transactions may be more favorable to new investors, and may include liquidation
preferences, superior voting rights or the issuance of other derivative securities, which could have a further dilutive effect on or
subordinate the rights of our current investors. Any additional capital raised through the sale of equity securities will likely dilute
the ownership percentage of our shareholders. Additionally, any debt securities we issue would likely create a liquidation preference
superior to that of our current investors and, if convertible into shares of common stock, would also pose the risk of dilution.

 We
may be unable to obtain necessary financing if and when required.

 Our
ability to obtain financing, if and when necessary, may be impaired by such factors as the capital markets (both in general and in the
particular industry or industries in which we may choose to operate), our limited operating history and lack of operations, the national
and global economies and the condition of the market for microcap securities. Further, economic downturns including the recession we
may be entering combined with high inflation and investor uncertainties may increase our requirements for capital, particularly if such
economic downturn persists for an extended period of time or after we have acquired an operating entity, and may limit or hinder our
ability to obtain the funding we require. If the amount of capital we are able to raise from financing activities, together with any
revenues we may generate from future operations, is not sufficient to satisfy our capital needs, we may be required to cease our operations,
divest our assets at unattractive prices or obtain financing on unattractive terms. If any of the foregoing should happen, our shareholders
could lose some or all of their investment.

 Risks
Related to Our Common Stock

 Due
to factors beyond our control, our stock price may be volatile.

 There
is currently a limited market for our common stock, and there can be no guarantee that an active market for our common stock will develop.
As of December 31, 2024, there were only 51 record holders of our common stock, and trading is very limited and sporadic. Further, even
if an active market for our common stock develops, it will likely be subject to significant price volatility when compared to more seasoned
issuers. We expect that the price of our common stock will continue to be more volatile than more seasoned issuers for the foreseeable
future. Fluctuations in the price of our common stock can be based on various factors in addition to those otherwise described in this
Report, including:

 The
 operating performance of the business, including any failure to achieve material revenues therefrom;

 The
 performance of our competitors in the marketplace;

 The
 public's reaction to our press releases, SEC filings, website content and other public announcements and information;

 Variations
 in general economic conditions, including as may be caused by uncontrollable events;

 The
 public disclosure of the terms of any financing we disclose in the future;

 The
 number of shares of our common stock that are publicly traded in the future;

 Actions
 of our existing shareholders, including sales of common stock by our then directors and then executive officers or by significant
 investors; and

 Many
of these factors are beyond our control and may decrease the market price of our common stock, regardless of our current or subsequent
operating performance and financial condition. In the past, following periods of volatility in the market price of a company's
securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial
costs and divert our management's time and attention, which would otherwise be used to benefit our business.

trading in our common stock is so limited, investors who purchase our common stock may depress the market if they sell common stock.

 Our
common stock trades on the OTC Pink Market, the successor to the pink sheets. The OTC Pink Market generally is illiquid and most stocks
traded there are of companies that are not required to file reports with the SEC under the Exchange Act. While we voluntarily file Forms
10-Q and 10-K with the SEC, we are a voluntary filer and not required to file reports with the SEC. Our common stock itself infrequently
trades.

 The
market price of our common stock may decline if a substantial number of shares of our common stock are sold at once or in large blocks.

 Presently
the market for our common stock is limited. If an active market for our shares develops in the future, some or all of our shareholders
may sell their shares of our common stock which may depress the market price. Further, Rule 144 will not be available since we are a
"shell" company, unless we become a mandatory filer and 12 months passes from the filing of what is called "Form 10"
information. Any sale of a substantial number of these shares in the public market, or the perception that such a sale could occur, could
cause the market price of our common stock to decline, which could reduce the value of the shares held by our other shareholders. Further,
the Term Sheet envisions that following of the closing we must file a Registration Statement on Form S-1 to register the common stock
issuable upon conversion of the preferred stock issued to the investors in conjunction with the closing. While the number of shares may
not be large, the filing of a Registration Statement often results in a drop in the price of a company's common stock.

 Future
issuances of our common stock could dilute the interests of our existing shareholders, particularly in connection with an acquisition
and any resulting financing.

 We
may issue additional shares of our common stock in the future. The issuance of a substantial amount of our common stock or securities
convertible, exercisable or exchangeable for our common stock could substantially dilute the interests of our shareholders. In addition,
the sale of a substantial amount of common stock in the public market, either in the initial issuance or in a subsequent resale by the
target company's former equity holders in a business combination which received our common stock as consideration, or by investors
who had previously acquired such common stock, could have an adverse effect on the market price of our common stock.

our common stock is subject to the " penny stock " rules, brokers cannot generally solicit the purchase of our
common stock, which adversely affects its liquidity and market price.

 The
SEC has adopted regulations which generally define "penny stock" to be an equity security that has a market price of less
than $5.00 per share, subject to specific exemptions. The market price of our common stock on the OTC Pink Market is presently less than
$5.00 per share and therefore we are considered a "penny stock" company according to SEC rules. Further, we do not expect
our stock price to rise above $5.00 in the foreseeable future. The "penny stock" designation requires any broker-dealer selling
our securities to disclose certain information concerning the transaction, obtain a written agreement from the purchaser and determine
that the purchaser is reasonably suitable to purchase the securities. These rules limit the ability of broker-dealers to solicit purchases
of our common stock and therefore reduce the liquidity of the public market for our shares.

 Moreover,
as a result of apparent regulatory pressure from the SEC and the Financial Industry Regulatory Authority ("FINRA"), a growing
number of broker-dealers decline to permit investors to purchase and sell or otherwise make it difficult to sell shares of penny stocks.
The "penny stock" designation may have a depressive effect upon our common stock price.

of FINRA sales practice requirements which affect broker-dealers, the market price for our common stock will be adversely affected.

 FINRA
has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing
that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional
customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status,
investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that
speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers
to recommend that their customers buy shares of our common stock, which may limit our shareholders' ability to buy and sell our
common stock and have an adverse effect on the market for our shares. Further, due to FINRA regulation, there are a limited number of
broker dealers which will handle penny stocks, which impairs the market and reduces the market price.

 Due
to changes to Rule 15c2-11 under the Securities Exchange Act of 1934, our common stock may become subject to limitations or reductions
on stock price, liquidity or volume.

 On
September 28, 2021, the SEC's amendments to Rule 15c2-11 under the Exchange Act became effective. This Rule applies to broker-dealers
who quote securities listed on over-the-counter markets such as our common stock. The Rule as amended prohibits broker-dealers from publishing
quotations on OTC markets for an issuer's securities unless they are based on current publicly available information about the
issuer. The amended Rule will also limit the Rule's "piggyback" exception, which allows broker-dealers to publish quotations
for a security in reliance on the quotations of a broker-dealer that initially performed the information review required by the Rule,
to issuers with current publicly available information or issuers that are up-to-date in their Exchange Act reports. As of this date,
we are uncertain as what actual effect the Rule may have on us.

 Upon
the effective date of the Rule amendments, the OTC Markets has passed a rule that permits shell companies to trade for only 18 months
after September 28, 2021. As a result, we will need to acquire an operating business within the prescribed timeframe in order for our
common stock to continue to be quoted on the OTC Pink Market.

 The
Rule changes could harm the liquidity and/or market price of our common stock by either preventing our shares from being quoted or driving
up our costs of compliance. Because we are a voluntary filer under Section 15(d) of the Exchange Act and not a public reporting company,
the practical impact of these changes is to require us to maintain a level of periodic disclosure we are not presently required to maintain,
which would cause us to incur material additional expenses. Further, if we cannot or do not provide or maintain current public information
about our company, our stockholders may face difficulties in selling their shares of our common stock at desired prices, quantities or
times, or at all, as a result of the amendments to the Rule.

we may issue preferred stock without the approval of our shareholders and have other anti-takeover defenses, it may be more difficult
for a third-party to acquire us and could depress our stock price.

 Our
Board may issue, without a vote of our shareholders, one or more series of preferred stock that have voting rights, liquidation preferences,
dividend rights and other rights that are superior to those of our common stock. Any issuance of preferred stock could adversely affect
the rights of holders of our common stock in that such preferred stock could have priority over the common stock with respect to voting,
dividend or liquidation rights. Further, because we can issue preferred stock having voting rights per share that are greater than the
equivalent of one share of our common stock, our Board could issue preferred stock to investors who support us and our management and
give effective control of our business to our management. Additionally, issuance of preferred stock could block an acquisition resulting
in both a drop in our stock price and a decline in interest of our common stock. This could make it more difficult for shareholders to
sell their common stock and/or cause the market price of our common stock shares to drop significantly, even if our business is performing
well.

 Item 1B. Cybersecurity

 To
date, the Company has not identified any cybersecurity incidents which have materially affected, or are reasonably likely to materially
affect, the Company's business strategy, results of operations or financial condition. The Company has not implemented any specific
policies with respect to monitoring and managing cybersecurity threats. Moreover, the Company is aware of the evolution of cybersecurity
risks and is taking proactive steps by keeping up to date our information systems and educating our personnel about these risks.

 The Company recognizes
the importance of developing, implementing, and maintaining cybersecurity measures to safeguard its information systems and protect the
confidentiality, integrity, and availability of the data. The Company will be looking to adopt cybersecurity processes, technologies
and controls to aid in its efforts to assess, prevent, identify and manage such risks.

 Item
2. Properties

 Our
principal place of business is 2722 S West Temple, Salt Lake City, UT 84115. We have a verbal month-to-month rental arrangement for our
office and inventory space. We believe that these facilities are adequate for our current needs. We do not own any real estate.

 Item
3. Legal Proceedings

 We
are not currently a party in any legal proceeding or governmental regulatory proceeding nor are we currently aware of any pending or
potential legal proceeding or governmental regulatory proceeding proposed to be initiated against us that would have a material adverse
effect on us or our business.

 Item
4. Mine Safety Disclosures

 Not

 PART
II

 Item
5. Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Market
Information

 Our
common stock is not listed on any securities exchange, and is quoted on the OTC Pink Market under the symbol "NOTR." Because
our common stock is not listed on a securities exchange and its quotations on the OTC Pink Market are limited and sporadic, there is
currently no established public trading market for our common stock.

 The
following table reflects the high and low closing sales information for our common stock for each fiscal quarter during the fiscal years
ended December 31, 2024 and 2023. This information was obtained from the OTC Pink Market and reflects inter-dealer prices without retail
mark-up, mark-down or commission and may not necessarily represent actual transactions.

 COMMON STOCK MARKET

 PRICE

 HIGH

 LOW

 FISCAL YEAR ENDED DECEMBER 31, 2024:

 First Quarter

 $
 9.01

 $
 9.01

 Second Quarter

 $
 1.00

 $
 1.00

 Third Quarter

 $
 1.00

 $
 1.00

 Fourth Quarter

 $
 1.00

 $
 1.00

 COMMON STOCK MARKET

 PRICE

 HIGH

 LOW

 FISCAL YEAR ENDED DECEMBER 31, 2023:

 First Quarter

 $
 18.00

 10.00

 Second Quarter

 $
 9.01

 9.01

 Third Quarter

 $
 9.01

 9.01

 Fourth Quarter

 $
 9.01

 9.01

 Number
of Holders

 As
of December 31, 2024, 43,916,221 shares of our common stock were issued and outstanding, which were held by 51 stockholders of record.

 Stock
Transfer Agent

 Our
stock transfer agent is Colonial Stock Transfer, 7840 S 700 E, Sandy, Utah 84070, (801) 355-5740, www.colonialstock.com.

 Dividends

 No
cash dividends were paid on our shares of common stock during the years ended December 31, 2024 and 2023. We have not paid any cash dividends
since our inception and do not foresee declaring any cash dividends on our common stock in the foreseeable future.

 Securities
Authorized For Issuance Under Equity Compensation Plans

 We
currently do not have any equity compensation plans.

 Recent
Sales of Unregistered Securities

the year 2023, the Company issued 1,063,621 common shares for cash proceeds of $265,000.

the year 2024, the Company issued 3,020,000 common shares for cash proceeds of $755,000.

 Item
6. Selected Financial Data

 Consistent
with the rules applicable to "smaller reporting entities", we have omitted the information required by Item 6.

 Item
7. Management ' s Discussion and Analysis of Financial Condition and Results of Operations

 Cautionary
Note Regarding Forward Looking Statements

 This
Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements
regarding our discussions and the anticipated terms of a potential reverse merger pursuant to which we would acquire an operating business,
our business plan and our liquidity needs. All statements other than statements of historical facts contained in this Report, including
statements regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations,
are forward-looking statements. The words "believe," "may," "estimate," "continue," "anticipate,"
"intend," "should," "plan," "could," "target," "potential," "is
likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking
statements. We have based these forward-looking statements largely on our current expectations and projections about future events and
financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

 The
results anticipated by any or all of these forward-looking statements might not occur. Important factors, uncertainties and risks that
may cause actual results to differ materially from these forward-looking statements include those described elsewhere in this Report
and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 under "Item 1A. – Risk Factors."
We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future
events or otherwise.

 Overview

 As
a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through
our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting
includes: Dementia and Alzheimer's disease, ADHD and ADD, Long Covid, General Energy, Traumatic Brain Injury, Mild Cognitive Decline,
GLP-1 Weight Loss, Sleep Improvement, Epilepsy and Seizure Reduction and Nasal Health and Allergy.

 A
trend that we believe is very beneficial and encouraging is the recent growing interest in mitochondria health and the role that mitochondria
dysfunction plays in mental health and physical health issues. Methylene Blue and specialty natural options has emerged as valuable foundational
health options on these fronts. We believe we are very well positioned and with adequate capital infusion we will be able to capitalize
on multiple market opportunities.

 The
ability of the Company to continue as a going concern is dependent upon the Company's ability to further implement its business
plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering.

 Plan
of Operation

 On
February 13, 2023, Nowtransit entered into the Exchange Agreement with Best and the shareholders of Best who collectively owned 9,588,000
shares of Best common stock, or 100% of the outstanding shares of Best common stock. The transaction consummated on March 10, 2023 (the
"Closing").

 Upon
the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company's common stock, representing approximately
85.39% of the shares of the Company's common stock to be outstanding, in exchange for all of the shares of Best common stock held
by Best shareholders. The transaction was accounted for as a reserve merger. Best was the accounting acquirer and Nowtransit the accounting
acquiree. As such, the consolidated financial statements presented are the historical financial statements of Best with retroactive adjustments
to reflect the equity of Nowtransit. Since Nowtransit was the legal acquirer, the resulting financial statements are in the name of Nowtransit.

the next 12 month period, the Company will continue to market and sell clinically-tested, affordably priced products to naturally battle
the onslaught of bacteria and viruses through online sales and in various other distribution channels. Presently, the Company is marketing
Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, EZ Safer Surface Cleaner, Be On-Guard Brain Fog Support and ADHD 365 maximum strength
brain support, NeuroPro Plus a patent pending combination of pharmaceutical grade methylene blue and vitamin C, TBI-365 to elevate your
brain health and wellness with pharmaceutical grade methylene blue, glucine, nac and niacinamide and Metabolism+ to enhance your metabolism.

 CRITICAL
ACCOUNTING POLICIES AND ESTIMATES

 Management's
discussion and analysis and results of operations are based upon our accompanying financial statements for the year ended December 31,
2024, which have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us
to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure
of contingent assets and liabilities. Note 4. Summary of Significant Accounting Policies, to the financial statements included in Part
I, Item 1 of this Annual Report on Form 10-K, describes the significant accounting policies and methods used in the preparation of the
Company's financial statements. We base our estimates on historical experience and on various other assumptions that we believe
are reasonable under the circumstances. These estimates are the basis for our judgments about the carrying values of assets and liabilities,
which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under
different assumptions or conditions.

 Results
Of Operations

 Year
Ended December 31, 2024 Compared to the Year Ended December 31, 2023

 Our
net income for the year ended December 31, 2024 was $87,000, compared to a net loss of $251,500 during the year ended December 31, 2023.
The Company has generated revenue of $1,844,966 and $597,595 during the year ended December 31, 2024 and 2023, respectively. The increase
in revenue is due to overall Company growth. The increase in net income was due to an increase in distributor and website sales. General
and administrative expenses incurred were $1,146,410, during the year ended December 31, 2024, compared to $706,257 during the year ended
December 31, 2023, also explained by the overall Company growth and additional expenses incurred to support our operations.

 LIQUIDITY
AND CAPITAL RESOURCES

 As
of December 31, 2024, our total assets were $873,788, consisting of cash, accounts receivable, inventory, prepaid expenses, overpayments
to related parties, and intangible assets.

 Cash
Flows from Operating Activities

 For
the year ended December 31, 2024, net cash flows provided by operating activities was $23,188, consisting of our net income of $87,000
offset by changes in operating activities of $63,812. For the year ended December 31, 2023, net cash flows used in operating activities
was $307,842, consisting of our net loss of $251,500 plus net changes in operating activities of $56,342.

 Cash
Flows from Investing Activities

 For
the year ended December 31, 2024, $26,037 was used to purchase an intangible asset.

 Cash
Flows from Financing Activities

 For
the year ended December 31, 2024 net cash flows provided by financing activities was $646,128, consisting, advances from related parties
of $962,848, $755,000 of cash acquired from the sale of common stock, offset by repayments to related parties of $1,071,720. For the
year ended December 31, 2023 net cash flows provided by financing activities was $315,511, consisting of cash acquired in recapitalization
of $8,793, advances from related parties of $613,973, $265,000 of cash acquired from the sale of common stock, offset by repayments to
related parties of $572,255.

 PLAN
OF OPERATION AND FUNDING

 Recently,
the Company completed the raise of $1,000,000 from a private placement to accredited investors. Now that the private placement is complete,
the Company will begin the due diligence process of evaluating and deciding on preparing and filing a Form 1-A with the SEC.

 The
Nowtransit management team plans to focus on gaining traction for its mental health and general wellness products. Best 365 Labs, Inc
has filed for a provisional patent on its mental wellness, natural products which is an additional reason we plan to focus and grow this
sector of the products. With the Global Mental Health Marketplace currently valued at $383.31 billion annually and with 41 million people
holding a prescription for Adderall that the market conditions are idea for us to offer our natural substitute product options (which
are also unique).

 As
a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in these potential marketplaces,
through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we
are targeting include:

 1.
Dementia and Alzheimer's Disease: The global market for dementia and Alzheimer's disease treatment and care is substantial,
with estimates ranging from tens to hundreds of billions of dollars annually. This includes spending on medications, long-term care,
home care services, assistive devices, and research efforts aimed at finding effective treatments and interventions.

 2.
ADHD and ADD: The market for ADHD and ADD treatment encompasses a wide range of products and services, including prescription medications,
therapy services, educational resources, and dietary supplements. In the United States alone, spending on ADHD medications exceeds several
billion dollars annually, with additional expenditures on other forms of treatment and support.

 3.
Long Covid: Long Covid is a relatively new condition, and the market size for treatments and support services is still emerging. However,
healthcare spending related to Covid-19, including both acute care and long-term management of post-Covid symptoms, is substantial and
continues to grow as the pandemic persists.

 4.
General Energy: The market for products and services aimed at boosting energy levels is vast and includes a wide range of offerings,
such as energy drinks, dietary supplements, nutritional products, fitness programs, and wellness services. Globally, this market is worth
billions of dollars annually and continues to expand as consumers seek ways to enhance their energy and vitality.

 5.
Traumatic Brain Injury (TBI): The market for TBI treatment and rehabilitation encompasses various healthcare services, medical devices,
pharmaceuticals, and assistive technologies. Estimates of the economic burden of TBI vary widely, but it is recognized as a significant
public health issue with substantial costs associated with medical care, long-term disability, and lost productivity.

 6.
Mild Cognitive Decline: The market for products and services targeting mild cognitive decline, such as cognitive training programs, dietary
supplements, and brain health assessments, is growing as awareness of cognitive health issues increases. While precise market size estimates
may be challenging to obtain, the demand for interventions to support cognitive function in aging populations is driving growth in this
sector.

 7.
GLP-1 Weight Loss Market: The global market for GLP-1 agonists used for weight loss is significant and continues to expand. According
to market research reports, the global GLP-1 agonists market was valued at several billion dollars in recent years, and it is projected
to continue growing at a steady rate.

 8.
Sleep Improvement/Sleep Health: The global sleep market is substantial and continues to grow. According to various market research reports,
the global sleep aids market was valued at several billion dollars in recent years, and it is projected to continue expanding at a steady
rate. This growth is driven by factors such as increasing awareness of the importance of sleep for overall health and well-being, rising
prevalence of sleep disorders, and the availability of a wide range of sleep products and services.

 9.
Epilepsy and Seizure Reduction: Epilepsy is one of the most common neurological disorders, affecting millions of people globally. According
to the World Health Organization (WHO), approximately 50 million people worldwide have epilepsy, making it a significant public health
concern. The high prevalence of epilepsy creates a substantial market for products and services aimed at reducing seizures and improving
quality of life for individuals with epilepsy.

 10.
Nasal Health and Allergy: This market includes pharmaceuticals, over-the-counter medications, nasal sprays, nasal irrigation devices,
allergy testing kits, allergy immunotherapy, and more. According to various market research reports, the global nasal drug delivery technology
market was valued at over $50 billion in 2020 and is projected to grow significantly in the coming years. Factors driving growth include
increasing prevalence of allergic rhinitis and other nasal disorders, technological advancements in drug delivery systems, growing demand
for over-the-counter allergy medications, and rising awareness about nasal health.

 Obstacles
to carve out space in these categories include access to adequate capital to carve out the profitable market niche and segments. We believe
we have a medical advisory team established (that a much larger company would be proud of); a leadership team that has innovated an initial
suite of products (portions of which are patent pending) and a sales and marketing team that is already starting to gain traction.

 A
trend that we believe is very beneficial and encouraging is the recent growing interest in mitochondria health and the role that mitochondria
dysfunction plays in mental health and physical health issues.

 Methylene
Blue and specialty natural options has emerged as valuable foundational health options on these fronts. We believe we are very well positioned
and with adequate capital infusion we will be able to capitalize on multiple market opportunities.

 To
establish our position in the emerging methylene blue marketplace and the many options and market segments we have put together a very
strong and diverse medical advisory team to advise, innovate/refine innovations, educate and develop protocols to promote optimal mitochondria
and overall mental and physical health.

 Our
Sales Plan and Channels

 The
plan is to commercialize and become a market leader within the Methylene Blue along with our specialty immune, nasal and allergy support
categories.

 Currently
we have started sales in the following categories:

 1.

 Amazon:
 We are currently selling all six products listed above at Amazon. The plan is to continue building this sales channel. We view this
 as an essential sales channel especially for credibility, and market acceptance.

 2.

 Wholesale
 Sales: We have developed an online platform at  to facilitate clinics, doctors, chiropractors,
 and other wholesalers to easily order our products. Through tradeshows we have already onboarded 700 clients to this portal. Sales
 are growing monthly and showing potential.

 3.

 Private
 Label Sales: We currently have three deals in place. We are being very selective on who we allow to private labels and it has to
 fit within a market category above that makes sense within our overall vision and growth.

 4.

 Direct
 Sales: We are revising our online platform at www. Best365Labs.com to capitalize better on SEO and Google ads. That being said
 sales are showing promise on this front.

 With
adequate capital infusion we can look at additional sales channels including traditional retail sales that require terms of 30-90 days.
Currently our wholesale clients are paying for their products in advance. We are also moving forward on establishing international distribution
opportunities.

 We
believe that the market for our patent pending methylene blue and specialty products will continue to expand and grow causing an organic
a natural growth cycle to occur.

 Our
Pharmaceutical Grade Methylene Blue Products (Patent Pending)

 NeuroPro+

 NeuroPro
Plus is a patent pending combination of Pharmaceutical Grade Methylene Blue and Vitamin C. Clinical data suggests the combination of
nutrients in NeuroPro Plus can be helpful nutritional support for anyone suffering from brain fog and anyone that wants more focus, concentration
and memory recall.

 Active
Daily Health Defense " ADHD " 365

 Active
Daily Health Defense "ADHD" 365 tablets are a patent pending combination of L-Theanine, Caffeine and Methylene Blue. Strong
clinical data suggests the exact combination of nutrients in ADHD-365 can be the perfect nutritional support for anyone that suffers
from ADHD as well as anyone that wants more mental energy, focus, concentration and memory recall.

 Brain
Fog Support

 Be-OnGuard
Brain Fog Support is an exclusive combination of tested nutrients only available in this formula including: Methylene Blue, Vitamin C
and Mineral Oxides. Be-OnGuard Brain Fog Support improves memory. One of the clinically tested active ingredients in our formula Methylene
Blue improves memory by increasing brain cell respiration. Or how the brain cell utilizes oxygen. Combined with our mineral oxide that
naturally harnesses the power of oxygen, you have a formula like none other. In addition, Vitamin C acts as a powerful antioxidant.

 Our
Immune and General Health Products

 Be-OnGuard
Nasal Spray

 Fast-acting
against airborne agents; Naturally assists with Neutralizing allergens and airborne contaminants; Helps moisten and assists to reduce
sinus inflammation for clearing of nasal passages. Proven Immune Support. Developed & Tested in Conjunction with a respiratory therapist.
Defend your Mouth & Throat Against Virus and Bacteria.

 Be-OnGuard
Mouth Spray

 Be-OnGuard
Mouth Spray is clinically tested against Bacteria and Viruses and can support your body's immune system. Be-OnGuard Mouth Spray
includes a clinically tested combination of an NSF 60 Mineral Oxide Water and Nano Silver that has been tested in-vitro against viruses
and bacteria.

 EZ
Safer Air

 EZ
Safer Air is 100% U.S. made with FDA approved all natural, organic, allergen free and non-toxic ingredients which makes it ideal for
living areas. EZ Safer Air is a clinically tested supercharged oxygenated water that is more powerful than ozonated water. Fill diffuser
or humidifier with water and then add one dropper full of EZ Safer Air solution. We recommend running it by your bed at night, in your
office, at home or any place you want to make safer naturally, to freshen and oxygenate the air.

 Patent
Pending Product Overview and Update

 New
U.S. Non-Provisional Patent Application No. 18/931,277 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024

 New
International Patent Application No. PCT/US24/53487 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024

 New
U.S. Non-Provisional Patent Application No. 18/931,346 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024

 New
International Patent Application No. PCT/US24/53490 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024. Filed
on 10/30/2024

 New
U.S. Provisional Patent Application No. 63/712,895 for TREATMENTS USING METHYLTHIONINIUM SALT, SECONDARY PHYSIOLOGICALLY ACTIVE COMPOUND
AND PHYSIOLOGICAL THERAPY, filed on 10/28/2024

 New
U.S. Provisional Patent Application No. 63/754,434 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS,
filed on 2/5/2025

 The
above-referenced provisional patent applications were filed in the United States Patent and Trademark Office ("Patent Office").
 These were filed for the company by law firm, Thorpe North and Western.

 We
believe that there are multiple potential patents within this offering. Leadership is exploring potential partnerships and strategic
alliances to monetize and capitalize for the stakeholder.

 OFF-BALANCE
SHEET ARRANGEMENTS

 We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 Going
Concern

 As
reflected in the consolidated financial statements, the Company has generated revenues resulting in a net income during the year ended
December 31, 2024. However, in the past the Company has reported losses and cash used in operating activities, thus resulting in an accumulated
deficit of $341,084 as of December 31, 2024. Additionally, over time the Company has relied on advances from related parties and proceeds
from the sale of stock, therefore has not yet developed a proven track record of profitability. These factors raise substantial doubt
about the Company's ability to continue as a going concern.

 The
Company is engaged in full-scale operations as a distributor and generates sufficient revenue; however, the Company's cash position
may not be sufficient to support the Company's daily operations long-term. Additionally, our business is subject to risks inherent
in marketing products in a competitive market as we continue to sell clinically-tested, affordably priced products to naturally battle
the onslaught of bacteria and viruses through online sales and in various other distribution channels. Management intends to raise additional
funds by way of a private or public offering. However, there can be no assurance that future financing will be available to us on acceptable
terms or at all. If financing is not available on satisfactory terms as and when needed, we may be unable to commence, develop or expand
our operations. Additionally, equity financing could result in additional dilution to existing stockholders. While the Company believes
in the viability of its strategy to commence operations and generate sufficient revenue and in its ability to raise additional funds,
there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company's
ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a
public or private offering.

 Item
7A. Quantitative and Qualitative Disclosures about Market Risk

 Not
applicable to smaller reporting companies.

 Item
8. Financial Statements and Supplementary Data

 Report of Independent Registered Public Accounting Firm (PCAOB ID: 6258)

 Consolidated Balance Sheets

 Consolidated Statements of Operations

 Consolidated Statements of Stockholders' Equity (Deficit)

 Consolidated Statements of Cash Flows

 Notes to the Consolidated Financial Statements

 REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 Board
of Directors and Shareholders

 Nowtransit
Inc.

 Opinion
on the Financial Statements

 We
have audited the accompanying balance sheets of Nowtransit Inc. as of December 31, 2024 and 2023, and the related statements of operations,
stockholders' equity (deficit), and cash flows for each of the two years then ended, and the related notes (collectively referred
to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the
financial position of Nowtransit Inc. as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each
of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 Going
Concern

 The
accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note
3 to the financial statements, the entity has suffered recurring losses from operations in the past and has an accumulated deficit because
the Company has not developed a proven track record of profitability. These matters raise substantial doubt about its ability to continue
as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.

 Basis
for Opinion

 These
financial statements are the responsibility of the entity's management. Our responsibility is to express an opinion on these financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) ("PCAOB") and are required to be independent with respect to Nowtransit Inc. in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We
conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. Nowtransit Inc. is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
entity's internal control over financial reporting. Accordingly, we express no such opinion.

 Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.

 Critical
Audit Matters

 Critical
audit matters arise from the current period audit of the financial statements that were communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. We determined there are no critical audit matters.

 /s/
 Mac Accounting Group & CPAs, LLP

 We
have served as Nowtransit Inc.'s auditor since 2022.

 Midvale,
Utah

 March
13, 2025

 NOWTRANSIT INC.

 CONSOLIDATED BALANCE SHEETS

 2024

 2023

 ASSETS

 Current Assets

 Cash and cash equivalents

 $
 662,517

 $
 19,238

 Accounts receivable, net

 100,285

 36,448

 Inventory

 58,319

 37,702

 Prepaid expense

 4,832

 -

 Overpayment to related parties

 21,798

 -

 Total current assets

 847,751

 93,388

 Other Assets

 Intangible assets

 26,037

 -

 Total Assets

 $
 873,788

 $
 93,388

 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 Current Liabilities

 Accounts payable

 $
 8,226

 $
 7,675

 Due to related parties

 -

 87,074

 Accrued expenses

 5,993

 1,450

 Deferred revenue

 24,329

 3,949

 Total current liabilities

 38,548

 100,148

 STOCKHOLDERS' EQUITY (DEFICIT)

 Preferred stock: $0.0001 par value, 5,000,000 shares
 authorized; 1,000,000 designated Series A Convertible

 -

 -

 Preferred stock: $ 0.0001 par value, 140,000 shares authorized; 140,000 shares issued and outstanding at December 31, 2024 and 2023, respectively

 Common stock: $ 0.0001 par value, 75,000,000 shares authorized; 43,916,221 and 40,896,221 shares issued and outstanding at December 31, 2024 and 2023, respectively

 4,391

 4,089

 Additional paid-in capital

 1,171,918

 417,220

 Accumulated deficit

 ( 341,083
)

 ( 428,083
)

 Total stockholders' equity (deficit)

 835,240

 ( 6,760
)

 Total Liabilities and Stockholders' Equity (Deficit)

 $
 873,788

 $
 93,388

 See accompanying notes to the consolidated financial statements.

 NOWTRANSIT INC.

 CONSOLIDATED STATEMENTS
OF OPERATIONS

 For the Year Ended

 2024

 2023

 Revenues

 $
 1,844,966

 $
 597,595

 Cost of goods sold

 ( 536,078
)

 ( 113,188
)

 Gross Profit

 1,308,888

 484,407

 Operating Expenses:

 General and administrative expenses

 1,146,410

 706,257

 Consulting fees

 75,478

 29,650

 Total Operating Expenses

 1,221,888

 735,907

 Income (Loss) from Operations

)

 Net Income (Loss)

 $

 $
)

 Net income (loss) per common share - basic

 $
 0.00

 $
 ( 0.01
)

 Net income (loss) per common share - diluted

 $
 0.00

 $
 ( 0.01
)

 Weighted average common shares outstanding - basic

 41,933,981

 33,764,675

 Weighted average common shares outstanding - diluted

 42,353,981

 33,764,675

 See accompanying notes to
the consolidated financial statements.

 NOWTRANSIT INC.

 CONSOLIDATED STATEMENTS
OF STOCKHOLDERS' EQUITY (DEFICIT)

 FOR THE YEAR ENDED DECEMBER 31, 2024
AND 2023

 Series A

 Additional

 Preferred Stock

 Common Stock

 Paid-in

 Accumulated

 Shares

 Amount

 Shares

 Amount

 Capital

 Deficit

 Total

 Balance at December 31, 2022

 140,000

 $

 5,461,500

 $

 $
 158,840

 $
 ( 176,583
)

 $
 ( 17,183
)

 Recapitalization March 10, 2023

 -

 -

 34,371,100

 3,437

 ( 6,514
)

 -

 ( 3,077
)

 Common shares issued for cash

 -

 -

 1,063,621

 264,894

 -

 265,000

 Net loss

 -

 -

 -

 -

 -

)

)

 Balance at December 31, 2023

 140,000

 40,896,221

 4,089

 417,220

 ( 428,083
)

 ( 6,760
)

 Common shares issued for cash

 -

 -

 3,020,000

 754,698

 -

 755,000

 Net income

 -

 -

 -

 -

 -

 Balance as December 31, 2024

 140,000

 $

 43,916,221

 $
 4,391

 $
 1,171,918

 $
 ( 341,083
)

 $
 835,240

 See accompanying notes to the consolidated financial statements.

 NOWTRANSIT INC.

 CONSOLIDATED STATEMENTS
OF CASH FLOWS

 For the Year Ended

 2024

 2023

 Cash Flows From Operating Activities

 Net Income (Loss)

 $

 $
)

 Adjustments to reconcile net loss to net cash used in
 operating activities

 -

 -

 Changes in operating assets and liabilities:

 Accounts receivable

 ( 63,837
)

 ( 28,687
)

 Inventory

 ( 20,617
)

 ( 25,424
)

 Deferred revenue

 20,380

 3,949

 Accrued expenses

 4,543

 1,450

 Accounts payable

 ( 7,630
)

 Prepaid expenses

 ( 4,832
)

 -

 Net Cash Provided by (Used in) Operating Activities

 23,188

 ( 307,842
)

 Cash Flows From Investing Activities

 Purchase of intangible assets

 ( 26,037
)

 -

 Net Cash Used in Investing Activities

 ( 26,037
)

 -

 Cash Flows From Financing Activities

 Advances from related parties

 962,848

 613,973

 Repayment to related parties

 ( 1,071,720
)

 ( 572,255
)

 Cash acquired in recapitalization

 -

 8,793

 Proceeds from the sale of common stock

 755,000

 265,000

 Net Cash Provided by Financing Activities

 646,128

 315,511

 Net Increase in Cash

 643,279

 7,669

 Cash at Beginning of Period

 19,238

 11,569

 Cash at End of Period

 $
 662,517

 $
 19,238

 Supplemental Cash Flow Information:

 Cash paid for interest

 $
 -

 $
 -

 Cash paid for income taxes

 $
 -

 $
 -

 See accompanying notes to the consolidated financial statements.

 NOWTRANSIT
INC

 NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS

 For
the years ended December 31, 2024 and 2023

 NOTE
1: ORGANIZATION AND BASIS OF PRESENTATION

 Nowtransit
Inc. (the "Company", "Nowtransit","us","we") was incorporated in the State of Nevada
on July 8, 2019. Through March 10, 2023 we had no operations and had not generated any material revenues since inception. Effective
March 10, 2023, we closed on a Share Exchange Agreement with Best 365 Labs Inc. ("Best"), a Nevada corporation, wherein
we acquired all of the shares of Best and Best became a wholly owned subsidiary of the Company (see Note 2).

 Best
was incorporated on October 12, 2021 in the State of Nevada. Best sells clinically-tested, affordably priced products to naturally battle
the onslaught of bacteria and viruses through online sales and in various other distribution channels. Presently, the Company is marketing
Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, EZ Safer Surface Cleaner, Be On-Guard Brain Fog Support and ADHD 365 maximum strength
brain support, NeuroPro Plus a patent pending combination of pharmaceutical grade methylene blue and vitamin C, TBI-365 to elevate your
brain health and wellness with pharmaceutical grade methylene blue, glucine, nac and niacinamide and Metabolism+ to enhance your metabolism.

 NOTE
2: REORGANIZATION & RECAPITALIZATION

 On
February 13, 2023, Nowtransit entered into a Share Exchange Agreement with Best and the shareholders of Best who collectively owned 9,588,000
shares of Best common stock, or 100 % of the outstanding shares of Best common stock. The transaction consummated on March 10, 2023 (the
"Closing").

 Upon
the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company's common stock (see Note 6), representing
approximately 85.39 % of the shares of the Company's common stock to be outstanding, in exchange for all of the shares of Best common
stock held by Best shareholders. The transaction was accounted for as a reserve merger by Nowtransit and resulted in a recapitalization
with Best being the accounting acquirer and Nowtransit being the accounting acquiree. As such, the consolidated financial statements
presented are the historical financial statements of Best with retroactive adjustments to reflect the equity of Nowtransit, and the operations
of Nowtransit from March 10, 2023, the effective date of the merger. Since Nowtransit was the legal acquirer, the resulting financial
statements are in the name of Nowtransit. All share and per share information in the accompanying consolidated financial statements and
footnotes have been retroactively restated to reflect the recapitalization.

 The
following table summarizes the assets acquired and the liabilities assumed at the acquisition date of March 10, 2023:

 Cash

 $
 8,793

 Accounts Payable

 ( 10,856
)

 Credit Card Liability

 ( 1,014
)

 Net Assets (Liabilities) Assumed

 $
 ( 3,077
)

 Had
Nowtransit and Best been combined since January 1, 2023 they would have reported revenues of $ 597,595, gross profit of $ 484,407, total
operating expenses of $ 755,017, and a net loss of $ 270,610 for the year ended December 31, 2023.

 NOTE
3: GOING CONCERN

 The
consolidated financial statements have been prepared on a going concern basis which assumes the Company will continue as a going concern,
which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

 As
reflected in the condensed consolidated financial statements, the Company has generated revenues resulting in a net income during the
year ended December 31, 2024. However, in the past the Company has reported losses and cash used in operating activities, thus resulting
in an accumulated deficit of $ 341,083 as of December 31, 2024. Additionally, over time the Company has relied on advances from related
parties and proceeds from the sale of stock, therefore has not yet developed a proven track record of profitability. These factors raise
substantial doubt about the Company's ability to continue as a going concern.

 The
Company is engaged in full-scale operations and generates sufficient revenue; however, the Company's cash position may not be sufficient
to support the Company's daily operations long-term. Management intends to raise additional funds by way of a private or public
offering. While the Company believes in the viability of its strategy to commence operations and generate sufficient revenue and in its
ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern
is dependent upon the Company's ability to further implement its business plan and generate sufficient revenue and its ability
to raise additional funds by way of a public or private offering.

 NOTE
4: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 Basis
of Presentation

 The
consolidated financial statements of the Company have been prepared on the accrual basis of accounting in accordance with generally accepted
accounting principles in the United States of America. The financial statements are presented in US dollars and the Company has adopted
a December 31 year end.

 Use
of Estimates

 The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates.

 Cash
and Cash Equivalents

 Cash
and cash equivalents include cash on hand, cash in banks and any highly liquid investments with a maturity of three months or less to
the extent the funds are not being held for investment purposes. As of December 31, 2024 and December 31, 2023, the Company had no cash
equivalents.

 The
Company maintains three accounts at Wells Fargo Bank. Accounts at this institution are insured by the Federal Deposit Insurance Corporation
up to $ 250,000.

 Accounts
Receivable and Allowance for Doubtful Accounts

 The
Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records
bad debt expense when deemed necessary. The Company records an allowance for doubtful accounts that is based on historical trends,
customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management's
estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to
collect a receivable have failed. As of December 31, 2024, 2023, and 2022 the Company had accounts receivable of $ 100,285, $ 36,448,
and $ 7,761, respectively. As of December 31, 2024, 2023, and 2022, the allowance for doubtful accounts was $ 0 and the Company
recorded no bad debt during the years then ended.

 Inventory

 The
Company's inventory is recognized in accordance with Accounting Standards Codification ("ASC") 303. The Company uses
the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of December 31,
2024 and 2023 the Company had $ 58,319 and $ 37,702 of finished goods on hand, respectively.

 Income
Taxes

 The
provision for income taxes and deferred income taxes are determined using the asset and liability method. Deferred tax assets and liabilities
are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using
enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company
assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative
evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered,
a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected
to be realized.

 The
income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from
continuing operations for the years ended December 31, 2024 and 2023, due to the following:

 December 31, 2024

 December 31, 2023

 Tax at statutory rate

 $
 22,620

 ( 26
)%

 $
 ( 65,390
)

 ( 26
)%

 Accrued consulting expense

 1,558

 ( 2
)%

 %

 Accrued related party advances

 -

 %

 22,639

 %

 Change in valuation allowance

 ( 24,178
)

 %

 42,374

 %

 Tax provision

 $
 -

 $
 -

 Deferred
income assets at December 31, 2023 and 2022 consisted of the following temporary differences and carry-forward items:

2024

2023

 Net Operating Loss Carryforwards

 $
 47,419

 $
 50,139

 Accrued consulting expenses

 1,558

 Accrued related party advances

 -

 22,639

 Valuation allowance

 ( 48,977
)

 ( 73,155
)

 Net Deferred tax asset

 $
 -

 $
 -

 The
Company has maintained a full valuation allowance against the total deferred tax assets due to the uncertainty of future utilization.

 As
of December 31, 2024, the Company had net federal and state net operating loss carry forwards of approximately $ 188,375 that may be used
to offset future taxable income and may be carried forward indefinitely with certain annual limitations on its use.

 Revenue
Recognition

 The
Company's revenue is recognized in accordance with Accounting Standards Codification 606 and operates in the immune health
supplement market. The Company offers products – Be-OnGuard Nasal Spray used against nasal bacteria, viruses and allergens;
Be-OnGuard Mouth Spray used against oral bacteria, viruses and allergens; and Be-OnGuard EZ Safer Air used against airborne
bacteria, viruses and allergens; Be-OnGuard Brain Fog Support; and ADHD 365 maximum strength brain support. The Company's
performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers will remit
payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred
revenue. As of December 31, 2024, 2023, and 2022 deferred revenue was $ 24,329, $ 3,949, and $ 0, respectfully. Returns and refunds have been minimal to date.
Accordingly, no provision has been made for any return or refund obligations as of December 31, 2024 and 2023.

 Advertising
Costs

 Advertising
costs are expensed as incurred. During the year ended December 31, 2024 and 2023, the Company incurred advertising costs of $ 132,716
and $ 111,042, respectively.

 Research
and Development

 The
Company charges research and development costs to expense when incurred. During the year ended December 31, 2024 and 2023, the Company
incurred $ 25,908 and $ 0 in research and development expenses, respectively.

 Intangible
Assets

 The
Company accounts for its intangible assets in accordance with ASC 350. Costs incurred to renew or extend the term of intangible assets
are expensed as incurred. During the year ended December 31, 2024, the Company incurred $ 26,037 to file certain patent applications that
showcase the Company's innovative approach to health and wellness solutions. The patent costs were capitalized and will be amortized
on a straight-line basis over its estimated useful life once the patents are granted. During the year ended December 31, 2024 and 2023
 no amortization expense was recorded as the patents were still pending. Amortization expense of $ 1,302 is expected for each of the years
ended December 31, 2025 and beyond.

 As
of December 31, 2024 the Company's patent applications include the following:

 Patent
Pending Product Overview and Update

 New
U.S. Non-Provisional Patent Application No. 18/931,277 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024

 New
International Patent Application No. PCT/US24/53487 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024

 New
U.S. Non-Provisional Patent Application No. 18/931,346 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024

 New
International Patent Application No. PCT/US24/53490 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024. Filed
on 10/30/2024

 New
U.S. Provisional Patent Application No. 63/712,895 for TREATMENTS USING METHYLTHIONINIUM SALT, SECONDARY PHYSIOLOGICALLY ACTIVE COMPOUND
AND PHYSIOLOGICAL THERAPY, filed on 10/28/2024

 New
U.S. Provisional Patent Application No. 63/754,434 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS,
filed on 2/5/2025

 Impairment
of Long-Lived Assets

 The
Company applies the provisions of ASC 360, where applicable, to all long-lived assets and periodically evaluates the carrying value of
long-lived assets to be held and used for impairment. Impairment losses are recorded on long-lived assets used in operations when indicators
of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying
amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived
assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for
the cost of disposal. When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed
from the accounts and any gain or loss is included in the results of operations. During the year ended December 31, 2024 and 2023, the
Company recorded no impairment expense for their long-lived assets.

 Leases

 The
Company follows the provisions of ASC 842, and records right-of-use ("ROU") assets and lease obligations for its operating
leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit
in the Company's leases is not readily determinable, the Company's applicable incremental borrowing rate is used in calculating
the present value of the sum of the lease payments. The lease term is defined as the non-cancelable period of the lease plus any options
to extend or terminate the lease when it is reasonably certain that the Company will exercise the option.

 The
Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial
term of 12 months or less.

 As
of December 31, 2024, the Company had a verbal month-to-month rental arrangement for their office and inventory space, therefore no ROU
asset or lease obligation was recorded. The Company recorded rent expense of $ 17,220 and $ 11,324 for the years ended December 31, 2024
and 2023, respectively.

 Net
Income (Loss) per Common Share

 Net
income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income
(loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding
during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number
of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution
that could occur from common shares issuable through contingent share arrangements, preferred stock conversions, stock options and warrants.
As of December 31, 2024 and 2023 there were dilutive securities of 420,000 for the conversion of Series A preferred stock. These potentially
dilutive securities were not included in the calculation of diluted net loss per common share at December 31, 2023 because they were
antidilutive, therefore as of December 31, 2023 basic net loss per share is the same as diluted net loss per share.

 Recent
Accounting Pronouncements

 The
Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements and has determined
that there have been no standards that had, or will have, a material impact on its consolidated financial statements.

 NOTE
5: RELATED PARTY TRANSACTIONS

 In
support of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company
can support its operations or attains adequate financing through sales of its equity or traditional debt financing. Amounts represent
advances or amounts paid in satisfaction of liabilities.

the year ended December 31, 2024 the Company purchased $ 444,785 worth of inventory from Ageless Global, LLC ("Global") and
Ageless Holdings, LLC ("Holdings"), entities owned and controlled by the Company's members of management and board
of directors. Additionally, the Company received $ 962,848 worth of advances from Global and Holdings and other entities owned and controlled
by the Company's members of management and the board of directors to pay for operating expenses (inclusive of amounts owed for
inventory sales) and the Company paid back $ 1,071,720 of the advances which included an overpayment of $ 21,798 as of December 31, 2024.

the year ended December 31, 2023 the Company purchased $ 157,010 worth of inventory from Holdings and the Company received $ 613,973 worth
of advances from Holdings and Global and other entities owned and controlled by the Company's members of management and the board
of directors to pay for operating expenses (inclusive of amounts owed for inventory sales) and the Company paid back $ 572,255 of the
advances. As of December 31, 2023 the amount due to related parties was $ 87,074.

 NOTE
6: EQUITY

 Common
Stock

 The
Company has 75,000,000, $ 0.0001 par value shares of voting common stock authorized.

the year ended December 31, 2024, the Company issued 3,020,000 common shares for cash proceeds of $ 755,000.

the year ended December 31, 2023, the Company issued 34,371,100 shares of common stock to Best shareholders in exchange for all of the
shares of Best common stock (see Note 2) resulting in an increase in common stock $ 3,437 and a decrease in additional paid-in-capital
of $ 6,514. During the year ended December 31, 2023, the Company issued 1,063,621 common shares for cash proceeds of $ 265,000.

 As
of December 31, 2024 and December 31, 2023, the Company had 43,916,221 and 40,896,221 shares of common stock issued and outstanding,
respectfully.

 Preferred
Stock

 On
October 19, 2021, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing up to 5,000,000 shares of
Preferred Stock, par value $ 0.0001 per share, with such rights, preferences and limitations as may be set forth in resolutions adopted
by the Board of Directors. On November 1, 2021, the Company filed a Certificate of Designation designating 1,000,000 shares of Preferred
Stock as Series A Convertible Preferred Stock (the "Series A"). Each share of the Series A is convertible into three shares
of the Company's common stock at the holder's election, subject to a 4.99% beneficial ownership limitation which may be increased
to 9.99% upon 61 days' notice.

the year ended December 31, 2024 there were no issuances of preferred stock. Nowtransit had issued 140,000 shares of Series A Convertible
Preferred Stock prior to the reorganization thus the shares were recorded at a zero net value in the consolidated financial statements.
As of December 31, 2024 and 2023, the Company had 140,000 shares of Series A Convertible Preferred Stock outstanding.

 NOTE
7: SUBSEQUENT EVENTS

 The
Company has evaluated all events that occur after the balance sheet date through March 13, 2025, the date when the financial statements
were available to be issued, to determine if they must be reported. Management of the Company determined that there are no material subsequent
events to be disclosed other than those described below.

 Subsequent
to December 31, 2024 the Company purchased $ 230,443 worth of inventory from related party entities owned and controlled by the Company's
members of management and board of directors. Additionally, the Company received $ 36,735 worth of advances from related party entities
owned and controlled by the Company's members of management and the board of directors to pay for operating expenses and the Company
used their overpayment of $ 21,798 and cash of $ 295,000 to make repayments on the advances.

 Effective February 21, 2025,
the Nowtransit board approved a resolution to change the name of the company to BioScience Health Innovations, Inc and filed the necessary
documents with the Nevada Secretary of State.

 Item
9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 None.

 Item
9A. Controls and Procedures

 Evaluation
of Disclosure Controls and Procedures

 Our
principal executive officer and our principal financial officer carried out an evaluation required by Rule 13a-15 or 15d-15 of the Securities
Exchange Act of 1934 (the "Exchange Act") of the effectiveness of our disclosure controls and procedures as defined in Rule
13a-15(e) or 15d-15(e) under the Exchange Act. Based on their evaluation, our principal executive officer and principal financial officer
concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report to ensure that
information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the SEC's rules and forms and is accumulated and communicated to our management
as appropriate to allow timely decisions regarding required disclosure.

 Management ' s
Report on Disclosure Controls and Procedures

 Management
is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)).
The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally
accepted in the United States of America. Our internal control over financial reporting includes those policies and procedures that (i)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of
our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements
in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance
with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of
management, including our principal executive officer and principal financial officer, the Company conducted an evaluation of the effectiveness
of the Company's internal control over financial reporting as of December 31, 2024 using the criteria established in "Internal
Control - Integrated Framework" issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013) ("COSO").

 Our
management assessed the effectiveness of our internal control over financial reporting based on the parameters set forth above and has
concluded that as of December 31, 2024, our internal control over financial reporting was not effective to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
U.S. generally accepted accounting principles as a result of the material weaknesses described below. A material weakness is a deficiency,
or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. Specifically,
in its assessment of the effectiveness of internal control over financial reporting as of December 31, 2024, the Company's management
determined that there were control deficiencies resulting in the following material weaknesses.

 1.

 The
 Company has an inadequate control environment. Specifically, there are no risk assessment, information or communication, or monitoring
 processes in place. Additionally, corporate governance is inadequate as a result of limited resources and oversight and the Company
 lacks policies that require formal written approval for related party transactions.

 2.

 The
 Company has inadequate control activities or formal accounting policies and procedures. Specifically, the Company lacks segregation
 of duties or adequate levels of supervision and review, there is a lack of information technology controls, and there are limited
 accounting resources with the appropriate knowledge of U.S. generally accepted accounting principles or SEC experience to ensure
 the financial reporting is free from material misstatements.

 Accordingly,
the Company's management concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement
of the annual or interim financial statements will not be prevented or detected on a timely basis by the Company's internal controls.

 As
a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control
over financial reporting as of December 31, 2024 based on criteria established in Internal Control—Integrated Framework issued
by COSO. We plan to rectify these weaknesses by implementing an independent Board of Directors, establishing written policies and procedures
for our internal control of financial reporting, and hiring additional accounting personnel at such time as we have sufficient funding
to do so.

 Changes
in Internal Control over Financial Reporting

 There
has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the
effectiveness of our internal control over financial reporting as of December 31, 2024, that occurred during our fourth fiscal quarter
that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 This
annual report does not include an attestation report of the Company's registered public accounting firm regarding internal control
over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting
firm pursuant to temporary rules of the SEC that permit the Company to provide only management's report in this annual report.

 Item
9B. Other Information.

 None.

 Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 Not

 PART
III

 Item
10. Directors, Executive Officers, and Corporate Governance

 Directors
and Executive Officers

 The
name, address and position of our present officers and directors are set forth below:

 Name and Address of Executive
 Officer and/or Director

 Age

 Position

 Darren Lopez

2722 S West Temple

Salt Lake City, UT 84115

 CEO, Chairman of the Board, and President

 John Chymboryk

2722 S West Temple

Salt Lake City, UT 84115

 Chief Financial Officer and Director

 Dan Schmidt

2722 S West Temple

Salt Lake City, UT 84115

 Chief Technology Officer

 Justin Earl

2825 East Cottonwood Parkway

Suite 500 - #5130

Salt Lake City, UT 84121

 Director

 Election
of Directors and Officers

 Directors
are elected to serve until the next annual meeting of stockholders and until their successors have been elected and qualified. Officers
are appointed to serve until the meeting of the Board following the next annual meeting of stockholders and until their successors have
been elected and qualified.

 Audit
Committee

 We
do not have any committees of the Board as we only have three directors. Our Board acts as the Company's Audit Committee as required.

 Director
Independence

 We
use the definition of "independence" of The Nasdaq Stock Market to make the determination of director independence. Nasdaq
Listing Rule 5605(a)(2) provides that an "independent director" is a person other than an officer or employee of the Company
or any other individual having a relationship, which, in the opinion of the Company's Board, would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director. Under such definitions, Justin Earl is considered an independent
director.

 Board
Leadership Structure

 We
have chosen to combine the President and Board Chairman positions.

 Code
of Ethics

 Our
Board has not adopted a Code of Ethics due to the Company's size and lack of employees.

 Delinquent
Section 16(a) Reports

 The
Company does not have a class of equity securities registered pursuant to Section 12 of the Exchange Act; therefore, this Item is not

 Item
11. Executive Compensation

 Compensation
of Executive Officers

 The
Company has paid the following compensation to its current or prior executive officers for the fiscal years ended December 31, 2024 and
December 31, 2023:

 Year Ended

 Officer

 2024

 2023

 Darren Lopez, CEO, Chairman of the Board, and President

 $
 120,000

 $
 -

 John Chymboryk, Chief Financial Officer

 $
 70,400

 $
 29,650

 Dan Schmidt, Chief Technology Officer and Director

 $
 119,653

 $
 39,780

 Justin Earl, Director

 $
 -

 $
 -

 Outstanding
Equity Awards at Fiscal Year End

 As
of December 31, 2024, none of our named executive officers held any unexercised options, stock awards that have not vested, or other
equity incentive plan awards.

 Director
Compensation

 To
date, we have not paid our directors any compensation for services on our Board.

 Employment
Agreements

 There
are no current employment agreements between the Company and, its officers, or other persons.

 Equity
Compensation Plan Information

 There
are no securities authorized for issuance under equity incentive plans, stock option plans, retirement, pension, or profit sharing plans
for the benefit of our officers, directors or employees.

 Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 The
following table shows the beneficial ownership of our common stock as of December 31 2024, held by (i) each person known to us to be
the beneficial owner of more than five percent (5%) of our common stock; (ii) each director; (iii) each executive officer; and (iv) all
directors and executive officers as a group. Beneficial ownership is determined in accordance with the rules of the SEC, and generally
includes voting power and/or investment power with respect to the securities held.

 Name of Beneficial Owner

 Shares of
 Common Stock
 Beneficially

Owned
 (1)

 % of
 Shares of
 Common Stock
 Beneficially

 Owned

 Ageless Holdings LLC – 3936 West Sugar Beet Dr, West Valley, UT 84120

 7,196,250

 16.39

 %

 Darren Lopez, CEO, Chairman of the Board, and President – 2722 S West Temple, SLC, UT 84115

 4,438,750

 10.11

 %

 Dan Schmidt, Chief Technology Officer – 2722 S West Temple, SLC, UT 84115

 5,000,000

 11.39

 %

 Justin Earl, Director – 2825 E Cottonwood Parkway, Suite 500, SLC, UT 84121

 2,800,000

 6.38

 %

 John Chymboryk, Chief Financial Officer – 2722 S West Temple, SLC, UT 84115

 1,775,000

 4.04

 %

 (1)
Applicable percentages are based on shares of common stock outstanding as of December 31, 2024. The number and percentage of shares beneficially
owned is determined in accordance with Rule 13d-3 and 13d-5 of the Exchange Act, and the information is not necessarily indicative of
beneficial ownership for any other purpose. Under SEC rules, a person is considered a "beneficial owner" of a security if
that person has or shares power to vote or direct the voting of such security or the power to dispose of such security. A person is also
considered to be a beneficial owner of any securities of which the person has a right to acquire beneficial ownership within 60 days.

 Item
13. Certain Relationships and Related Transactions, and Director Independence

 Related
Party Transactions

 In
support of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company
can support its operations or attains adequate financing through sales of its equity or traditional debt financing. Amounts represent
advances or amounts paid in satisfaction of liabilities.

the year ended December 31, 2024 the Company purchased $444,785 worth of inventory from Ageless Global, LLC ("Global") and
Ageless Holdings, LLC ("Holdings"), entities owned and controlled by the Company's members of management and board
of directors. Additionally, the Company received $962,848 worth of advances from Global and Holdings and other entities owned and controlled
by the Company's members of management and the board of directors to pay for operating expenses (inclusive of amounts owed for
inventory sales) and the Company paid back $1,071,720 of the advances which included an overpayment of $21,798 as of December 31, 2024.

the year ended December 31, 2023 the Company purchased $157,010 worth of inventory from Holdings and the Company received $613,973 worth
of advances from Holdings and Global and other entities owned and controlled by the Company's members of management and the board
of directors to pay for operating expenses (inclusive of amounts owed for inventory sales) and the Company paid back $572,255 of the
advances. As of December 31, 2023 the amount due to related parties was $87,074.

 Item
14. Principal Accountant Fees and Services

 The
following table shows the fees paid to our principal accountant for the fiscal years ended December 31, 2024 and 2023.

 Fiscal Year Ended

2024

 Fiscal Year Ended

 2023

 Audit Fees (1)

 $
 48,000

 $
 32,000

 Audit Related Fees (2)

 -

 -

 Tax Fees (3)

 -

 -

 All Other Fees (4)

 -

 -

 Total

 $
 48,000

 $
 32,000

 (1)

 Audit
 fees consist of fees incurred in connection with the audit of our annual financial statements and the review of the interim financial
 statements included in our quarterly reports filed with the SEC.

 (2)

 Audit
 Related Fees consist of the aggregate fees billed for professional services rendered for assurance and related services that were
 reasonably related to the performance of the audit or review of our financial statements and were not otherwise included in Audit
 Fees.

 (3)

 Tax
 Fees consist of the aggregate fees billed for professional services rendered for tax compliance, tax advice and tax planning. Included
 in such Tax Fees are fees for preparation of our tax returns and consultancy and advice on other tax planning matters.

 (4)

 All
 Other Fees consist of the aggregate fees billed for products and services provided and not otherwise included in Audit Fees, Audit
 Related Fees or Tax Fees. Included in such Other Fees are fees for services rendered in connection with any private and public offerings
 or registration statements conducted during such periods.

 PART
II. OTHER INFORMATION

 Item
1. Legal Proceedings

 Management
is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As
of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii)
has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been
threatened against us or our properties.

 Item
2. Unregistered Sales Of Equity Securities and Use Of Proceeds

the year 2023, the Company issued 1,063,621 common shares for cash proceeds of $265,000.

the year 2024, the Company issued 3,020,000 common shares for cash proceeds of $755,000.

 Item
3. Defaults Upon Senior Securities

 Not

 Item
4. Mine Safety Disclosures

 Not

 Item
5. Other Information

 Not

 PART
IV

 Item
15. Exhibits

 Exhibits:

 Exhibit #

 Exhibit Description

 Incorporated By Reference

 Filed or Furnished Herewith

 Form

 Date

 Number

 3.1(a)

 Articles of Incorporation

 S-1

 11/4/2019

 3.1

 3.1(b)

 Amendment to Articles of Incorporation

 11/26/2021

 3.1(B)

 3.2

 Bylaws

 S-1

 11/4/2019

 3.2

 3.3

 Certificate of Designation of Series A Convertible Preferred Stock

 11/26/2021

 3.3

 31.1

 Certification of Principal Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

 Filed

 31.2

 Certification of Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

 Filed

 32.1

 Certification of Principal Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

 Filed

 32.2

 Certification of Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

 Filed

 Interactive data files pursuant to Rule 405 of Regulation S-T

 Filed

 Filed

 Item
16. Form 10-K Summary

 None.

 SIGNATURES

 In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

 Nowtransit Inc.

 Dated: March 13, 2025

 By:

 / s / Darren Lopez

 Darren Lopez

 Chief Executive Officer, Chairman of the Board, and President

 (Principal Executive Officer)

 Dated: March 13, 2025

 By:

 / s / John Chymboryk

 John Chymboryk

 Chief Financial Officer

 (Principal Financial Officer)

 Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

 Name

 Title

 Date

 /s/
 Darren Lopez

 Principal
 Executive Officer

 March
 13, 2025

 Darren
 Lopez

 0001784440 false FY

 2025-03-12

 2024-06-30

 us-gaap: PreferredStockMember

 us-gaap: PreferredStockMember

 us-gaap: PreferredStockMember

 2023-02-13
 2023-02-13

 2023-02-13

 2023-03-10
 2023-03-10

 2023-03-10

 2023-03-10

 notr: AccruedConsultingExpenseMember

 notr: AccruedConsultingExpenseMember

 notr: RelatedPartyAdvancesMember

 notr: RelatedPartyAdvancesMember

 us-gaap: SeriesAPreferredStockMember

 us-gaap: SeriesAPreferredStockMember

 us-gaap: SubsequentEventMember

 2025-03-13

 us-gaap: SubsequentEventMember

 2025-01-01
 2025-03-13

 2024-10-01